SIGLEC15 and acute myeloid leukemia: Currently, several Siglec15 inhibitors are undergoing clinical trials, including NextCure’s NC318 for solid cancer (phase II), Medimmune for AML (patent filed), and Daichi Sankyo’s DS-1501 (phase I) (16).